Physiomics PLC - London-based mathematical modelling company that supports oncology drug development - Has been awarded a further contract by existing client Merck KGaA involving pre-clinical and clinical modelling and simulation of anti-cancer regimens involving combinations of DNA damage and repair agents. Follows on previous Merck-commissioned projects. Expects the contract award to be completed over the next three months.

Physiomics Chief Executive Officer Jim Millen says: ‘We are pleased that this longstanding client has once again chosen Physiomics as a partner for outsourced modelling. We look forward to the possibility of further projects with Merck during the current financial year.’

Current stock price: 0.98 pence, up 0.4%

12-month change: down 61%

Copyright 2023 Alliance News Ltd. All Rights Reserved.